Pulmonx Corp
LUNG- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001127537
In the last 90 days, Pulmonx Corp insiders filed 0 open-market purchases and 4 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $34.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $177.0K in total
- 4
- 13F holdersQ2 2026, −6 vs. previous quarter
- 107
- 13F valueReported value at the end of Q2 2026
- $34.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LUNG, Q2 2026
No superinvestor reported holding LUNG at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Pulmonx Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)6:23 PM ET | Sep 1 | 2 days | French Glendon E. IIIPresident and CEO | SSale | −41.9K | $2.26 | −$94.7K | −3.5%1.14M after | 2 lots |
| Sep 3, 2026 (view filing)6:21 PM ET | Sep 1 | 2 days | Radhakrishnan SrikanthChief Science & Techn. Officer | SSale | −14.2K | $2.26 | −$32.2K | −4.3%317.0K after | 4 lots |
| Sep 3, 2026 (view filing)6:19 PM ET | Sep 1 | 2 days | Lehman David AaronGeneral Counsel | SSale | −14.3K | $2.26 | −$32.4K | −3.8%361.8K after | 4 lots |
| Sep 3, 2026 (view filing)6:17 PM ET | Sep 1 | 2 days | Rose Geoffrey BeranChief Commercial Officer | SSale | −7.88K | $2.26 | −$17.8K | −1.7%449.8K after | 4 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Radhakrishnan SrikanthChief Science &Techn. Officer | SSale | −14.5K | $1.54 | −$22.3K | −4.2%331.2K after | 4 lots |
| Jun 3, 2026 (view filing) | Jun 1-2 | 2 days | French Glendon E. IIIPresident and CEO | SSale | −56.1K | $1.55 | −$86.9K | −4.5%1.18M after | 3 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER | SSale | −8.02K | $1.54 | −$12.4K | −1.7%457.7K after | 4 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Lehman David AaronGENERAL COUNSEL | SSale | −14.6K | $1.54 | −$22.5K | −3.7%376.2K after | 4 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Radhakrishnan SrikanthChief Science &Techn. Officer | SSale | −10.5K | $1.43 | −$15.0K | −5.8%170.7K after | 4 lots |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | French Glendon E. IIIPresident and CEO | SSale | −67.8K | $1.43 | −$97.0K | −4.6%1.41M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pulmonx Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Primecap Management Co | 4,612,331 | $6.00M | 0.00% | −112,660−2.4% | Reduced |
| Morgan Stanley | 2,922,921 | $3.80M | 0.00% | −1,070,641−26.8% | Reduced |
| Soleus Capital Management, L.P. | 2,788,323 | $3.62M | 0.12% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,630,219 | $2.12M | 0.00% | −4,045−0.2% | Reduced |
| ExodusPoint Capital Management, LP | 1,223,555 | $1.59M | 0.01% | −720,279−37.1% | Reduced |
| Almitas Capital LLC | 1,064,202 | $1.38M | 0.33% | +1,064,202 | New |
| BlackRock, Inc. | 882,490 | $1.15M | 0.00% | −1,779,117−66.8% | Reduced |
| Stonepine Capital Management, LLC | 815,436 | $1.06M | 0.81% | +47,148+6.1% | Added |
| Jane Street Group, LLC | 758,231 | $985.7K | 0.00% | +624,961+468.9% | Added |
| Braidwell LP | 752,541 | $978.3K | 0.04% | 00.0% | Unchanged |